greeksoup/ stock research
Stock research / United States / PTGX / FY2017

Protagonist Therapeutics (PTGX) FY2017 results: revenue $20 million

Protagonist Therapeutics, Inc. (PTGX) reported revenue of $20 million for fiscal 2017, the year ended 31 December 2017. Net income was -$37 million, and diluted earnings per share $-2.09. The figures are the company's own, from the 10-K it filed with the SEC on 12 March 2019.

Revenue
$20 million
FY2017FY2017
Operating margin
-188.9%
FY2017FY2017
Net income
-$37 million
FY2017FY2017
Diluted EPS
-$2.09
FY2017FY2017

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2017Last 8 years
Revenue20.1
Research and development46.2
Operating income-37.9
Operating margin-188.9%
Pre-tax income-37.0
Income tax0.0
Net income-37.0
Net margin-184.2%
Diluted EPS-$2.09
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2017Last 8 years
Operating cash flow3.9
Capital expenditure0.7
Free cash flow3.2
Free cash flow margin16.0%
Cash from investing15.8
Cash from financing65.6
Depreciation and amortisation0.4
Share-based compensation4.2
Shares outstanding at period end21m

Balance sheet

$ millionFY2017Last 8 years
Shareholders' equity121
Debt0.0
Other liabilities43.1
Total liabilities and equity164
Fixed assets0.9
Investments49.4
Cash and equivalents106
Other assets7.4
Total assets164

10-K for the year ended 31 December 2017, filed 12 March 2019: the filing.